Table 4.
Arterial substrate concentrations and myocardial substrate uptake
| Plasma Insulin, μU/ml |
Arterial Glucose, mmol/l |
Glucose Uptake, μmol·g−1·min−1 |
Arterial Lactate, mmol/l |
Lactate Uptake, μmol·g−1·min−1 |
Arterial FFA, mmol/l |
FFA Uptake, μmol·g−1·min−1 |
|
|---|---|---|---|---|---|---|---|
| Preischemia | |||||||
| Untreated | 4±1 | 4.0±0.2 | 0.19±0.04 | 1.2±0.2 | 0.63±0.11 | 0.16±0.04 | 0.02±0.02 |
| Troglitazone | 2±1 | 3.8±0.2 | 0.15±0.04 | 1.3±0.1 | 0.87±0.10‡ | 0.12±0.03 | 0.02±0.02 |
| Rosiglitazone | 3±1 | 4.2±0.1 | 0.17±0.04 | 1.0±0.1 | 0.66±0.07 | 0.10±0.04 | 0.00±0.01 |
| α-Tocopherol | 3±0 | 4.0±0.0 | 0.22±0.09 | 0.8±0.1 | 0.52±0.09‡ | 0.16±0.05 | 0.00±0.03 |
| Ischemia | |||||||
| Untreated | 4±1 | 4.1±0.2 | 0.33±0.05 | 1.0±0.1 | −0.28±0.05 | 0.09±0.03 | 0.01±0.01 |
| Troglitazone | 4±2 | 4.2±0.4 | 0.25±0.07 | 1.6±0.1* | −0.14±0.04‡ | 0.08±0.02 | 0.00±0.00 |
| Rosiglitazone | 4±1 | 4.3±0.1 | 0.42±0.08 | 1.1±0.1 | −0.26±0.10 | 0.06±0.01 | 0.01±0.01 |
| α-Tocopherol | 4±1 | 4.1±0.1 | 0.26±0.11 | 1.1±0.1 | −0.10±0.11‡ | 0.06±0.02 | 0.00±0.01 |
| Reperfusion | |||||||
| Untreated | 5±1 | 3.9±0.1 | 0.23±0.04 | 0.9±0.4 | 0.10±0.05 | 0.10±0.02 | 0.02±0.01 |
| Troglitazone | 6±2 | 3.7±0.2 | 0.21±0.02 | 1.3±0.2 | 0.39±0.03‡ | 0.05±0.01 | 0.01±0.00 |
| Rosiglitazone | 5±1 | 4.3±0.1 | 0.31±0.11 | 1.1±0.1 | 0.25±0.05 | 0.05±0.02 | 0.00±0.01 |
| α-Tocopherol | 3±0 | 4.0±0.1 | 0.19±0.06 | 1.2±0.1 | 0.38±0.18‡ | 0.07±0.03 | 0.03±0.02 |
Values are means ± SE; n = 15 (untreated), n = 6 (troglitazone), n = 12 (rosiglitazone), and n = 7 (α-tocopherol). FFA, free fatty acid.
*
P < 0.05 vs. other groups.
‡
P < 0.05 vs. untreated and rosiglitazone groups over the course of the experiment.